Valerie Morisset
Fondateur chez ELIEM THERAPEUTICS, INC.
Fortune : 2 M $ au 30/06/2024
Provenance du réseau au premier degré de Valerie Morisset
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
| Public Company | Biotechnology | 14 | |
Bridge Valley Ventures LLP
 Bridge Valley Ventures LLP Investment ManagersFinance Bridge Valley Ventures LLP is a Venture Capital firm founded in 2017. Bridge Valley Ventures LLP is headquartered in Cambridge.
3
| Private Company | Investment Managers | 3 |
Eliem Therapeutics (UK) Ltd.
 Eliem Therapeutics (UK) Ltd. BiotechnologyHealth Technology Eliem Therapeutics (UK) Ltd. is based in Altrincham, UK. Part of RA Capital Management LP, Eliem Therapeutics (UK) Ltd. is a British company that engages in research and development on biotechnology. Founded in 2019.
2
| Subsidiary | Biotechnology | 2 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Valerie Morisset via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
Convergence Pharmaceuticals Ltd.
 Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Founder Corporate Officer/Principal | |
| ALDER BIOPHARMACEUTICALS, INC. | Pharmaceuticals: Major | General Counsel Chief Executive Officer Chief Operating Officer | |
| AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Arvinas Operations, Inc.
 Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | Biotechnology | Director/Board Member Director/Board Member | |
| ARVINAS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
| University of Michigan | College/University | Masters Business Admin Masters Business Admin | |
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Investment Managers | Private Equity Investor Private Equity Investor | |
| EXELIXIS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal General Counsel | |
| Princeton University | College/University | Undergraduate Degree | |
Tang Capital Management LLC
 Tang Capital Management LLC Investment ManagersFinance Tang Capital Management LLC (Tang Capital) is an independent hedge fund manager headquartered in San Diego, California. The firm was founded by Kevin Tang in 2002. Tang Capital provides investment advice to high-net-worth clients. | Investment Managers | Analyst-Equity | |
| Vzenium LLC | Founder | ||
Cavion, Inc.
 Cavion, Inc. Pharmaceuticals: MajorHealth Technology Cavion, Inc. engages in development of pharmaceuticals products. It produces oncology drugs to treat solid tumors that selectively inhibits the t-type calcium channel. The company was founded by Andrew J. Krouse, Lloyd S. Gray, and Timothy L. Macdonald in 2005 and is headquartered in Charlottesville, VA. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| NEUROBO PHARMACEUTICALS, INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
| Humboldt-Universität zu Berlin | College/University | Doctorate Degree | |
| University of Antwerp | College/University | Doctorate Degree | |
| ALZHEON, INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
| Massachusetts Institute of Technology | College/University | Doctorate Degree | |
| University Of Dundee | College/University | Graduate Degree | |
| INTERMEDIATE CAPITAL GROUP PLC | Financial Conglomerates | Corporate Officer/Principal | |
GlaxoSmithKline, Inc.
 GlaxoSmithKline, Inc. Pharmaceuticals: MajorHealth Technology GlaxoSmithKline, Inc. manufactures and markets pharmaceutical products. The company develops medicines to prevent infections that cause serious medical problems such as respiratory illnesses, diabetes, viral control, infections, and central nervous system disorders. The company is headquartered in Mississauga, Canada. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| BIOGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Clinton Group, Inc.
 Clinton Group, Inc. Investment ManagersFinance Clinton Group, Inc. is a registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by George E. Hall in 1991 and is a subsidiary of Madison Avenue Capital Holdings, Inc., which is owned by CGI Holdings, Inc. Clinton Group serves as investment manager primarily for an offshore private investment fund, as well as pools of collateralized debt obligations (CDOs), collateralized bond obligations (CBOs) and other structured products for which the the firm as collateral manager. | Investment Managers | Corporate Officer/Principal | |
| H.I.G. BioVentures Advisors LLC | Corporate Officer/Principal | ||
H.I.G. BioHealth Partners LLC
 H.I.G. BioHealth Partners LLC Investment ManagersFinance H.I.G. BioHealth Partners LLC (H.I.G. BioHealth Partners) is a private equity and venture capital subsidiary of H.I.G. Ventures LLC founded in 1993. The firm is headquartered in Miami, Florida with additional offices around the globe. | Investment Managers | Private Equity Investor | |
| JUNO THERAPEUTICS INC | Biotechnology | Corporate Officer/Principal | |
| Harvard Medical School | College/University | Doctorate Degree | |
Clinton Health Access Initiative
 Clinton Health Access Initiative Miscellaneous Commercial ServicesCommercial Services The Clinton Health Access Initiative (CHAI) is a health organization that is dedicated to saving lives, reducing the burden of disease, and strengthening health systems. CHAI is based in Boston, MA, and the CEO of the non-profit company is Deepak Verma. The organization's focus is on improving healthcare in developing countries. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Lusaris Therapeutics, Inc.
 Lusaris Therapeutics, Inc. BiotechnologyHealth Technology Lusaris Therapeutics, Inc. is a biotechnology company that focuses on developing next-generation serotonergic neuroplastogen therapeutics to treat severe neuropsychiatric and neurological disorders. The company is based in Boston, MA. The company's lead program, LSR-1019, is a proprietary sublingual formulation of 5-MeO-DMT, a rapidly acting and rapidly clearing serotonergic psychedelic, which is being developed to treat treatment-resistant depression and other neuropsychiatric conditions. The company's pipeline also includes novel neuroplastogens for a wide range of neuropsychiatric and neurological conditions, including migraine and cluster headache. The CEO of the company is Andrew D. Levin. | Biotechnology | Chief Executive Officer | |
Imbria Pharmaceuticals, Inc.
 Imbria Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Imbria Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing novel therapies that restore cellular energy deficits. It focuses on restoring or improving the cell?s ability to produce energy where energy imbalances are at the root of disease, including cardiovascular diseases and inborn errors of metabolism. The company was founded by Andrew Levin and David-Alexandre C. Gros in 2018 and is headquartered in Boston, MA. | Pharmaceuticals: Major | Founder | |
Clear Creek Bio, Inc.
 Clear Creek Bio, Inc. Pharmaceuticals: MajorHealth Technology Clear Creek Bio, Inc. engages in the development of therapies that target nucleotide synthesis pathways. The firm focuses on the differentiation blockade in cancer and suppress replication of RNA-based viruses. It uses pharmacodynamic markers to ensure that each patient gets the right drug at the correct dose. The company was founded by David T. Scadden, David B. Sykes, Burt A. Adelman, and Vikram Sheel Kumar in 2017 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
| SYNTHORX, INC. | Biotechnology | Director/Board Member | |
RA Capital Management LP
 RA Capital Management LP Investment ManagersFinance RA Capital Management LP (RA Capital) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in Boston, Massachusetts. The firm was founded by Peter Kolchinsky in 2004. RA Capital provides discretionary investment advisory services to Healthcare Funds and the Nexus Funds which are open only to certain financially sophisticated and high net-worth individuals and entities. | Investment Managers | Portfolio Manager-Equities | |
H.I.G Capital LLC (Private Equity)
 H.I.G Capital LLC (Private Equity) Investment ManagersFinance H.I.G. Capital LLC (H.I.G Capital) is a private equity division of H.I.G. Capital LLC founded in 1993 by Sami W Mnaymneh and Anthony A Tamer. The firm is headquartered in Miami, Florida with offices in Europe, Latin America and Middle East. | Investment Managers | Private Equity Investor | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal | |
Superluminal Medicines Inc
 Superluminal Medicines Inc BiotechnologyHealth Technology Superluminal Medicines Inc is a generative biological and chemical company. The company is based in Boston, MA. The CEO of the company is Cony D'Cruz. | Biotechnology | Director/Board Member | |
| University of Virginia | College/University | Undergraduate Degree | |
| Wesleyan University | College/University | Doctorate Degree | |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | College/University | Graduate Degree | |
DomainTools LLC
 DomainTools LLC Packaged SoftwareTechnology Services DomainTools provides security system threat intelligence. Its products include IRIS investigation platform, phisheye, API integration, and personal domain research. The firm solutions include threat hunting, regulatory compliance, online fraud investigation, and phishing detection. The company is headquartered in Seattle, WA. | Packaged Software | Comptroller/Controller/Auditor | |
Teva Pharmaceuticals USA, Inc.
 Teva Pharmaceuticals USA, Inc. Pharmaceuticals: MajorHealth Technology Teva Pharmaceuticals USA, Inc. engages in the manufacturing and marketing of generic pharmaceuticals. The firm also provides medical affairs, quality plus safety and trade partner services. The company was founded in 1985 and is headquartered in Parsippany, NJ. | Pharmaceuticals: Major | General Counsel | |
| Lehigh University | College/University | Graduate Degree | |
| Clarkson University | College/University | Undergraduate Degree | |
| BRAEBURN INC. | Miscellaneous Commercial Services | General Counsel | |
Vitaeris, Inc.
 Vitaeris, Inc. BiotechnologyHealth Technology Vitaeris, Inc. develops new treatment options for chronic inflammatory diseases. The company was founded by Kevin Chow, Patrick A. Robinson and Noel F. Hall in 2016 and is headquartered in Vancouver, Canada. | Biotechnology | Director/Board Member |
Statistiques
Internationale
| Etats-Unis | 40 |
| Royaume-Uni | 7 |
| Canada | 3 |
| Allemagne | 2 |
| Belgique | 2 |
Sectorielle
| Health Technology | 27 |
| Consumer Services | 12 |
| Finance | 9 |
| Commercial Services | 3 |
| Technology Services | 2 |
Opérationnelle
| Director/Board Member | 78 |
| Independent Dir/Board Member | 26 |
| Corporate Officer/Principal | 25 |
| Undergraduate Degree | 11 |
| Chief Executive Officer | 10 |
Relations les plus connectées
| Insiders | |
|---|---|
| Liam Ratcliffe | 32 |
| Andrew Levin | 22 |
| Allan P. Marchington | 19 |
| Robert Azelby | 15 |
| Leone Patterson | 14 |
| Adam Rosenberg | 13 |
| Judith Dunn | 10 |
| Simon Tate | 9 |
| Mark Versavel | 8 |
| James Bucher | 7 |
| Erin Lavelle | 6 |
| Susan Franks | 5 |
| Michael Hoyne | 4 |
| Emily Pimblett | 4 |
| Joanne Palmer | 3 |
- Bourse
- Insiders
- Valerie Morisset
- Connexions Sociétés
